US-based medical device company Cordis has initiated the SELUTION Global Coronary Registry, a significant step in advancing evidence-based practice in cardiovascular care.
The registry aims to enrol up to 10,000 patients globally, making it one of the largest of its kind for coronary drug-eluting balloons.
The initiative will track real-world outcomes of the SELUTION SLR drug-eluting balloon for up to five years, complementing ongoing randomised trials.
The SELUTION SLR drug-eluting balloon has shown consistent effectiveness, with pre-clinical studies indicating sustained Sirolimus presence in tissue for 90 days.
Cordis chief medical officer George Adams said: “The history of Cordis is grounded in a commitment to clinical evidence; putting patients first means backing our technology with the strongest evidence we can provide.
“The launch of the SELUTION Global Coronary Registry reaffirms this commitment. We look forward to sharing groundbreaking coronary results this Fall.”
Clinical evaluations have demonstrated favourable late lumen loss measurements.
The registry builds on five ongoing Level 1 randomised trials and positive peripheral experience results, reinforcing Cordis’ goal of developing clinical evidence.
Cordis has assembled a steering committee of internationally recognised interventional cardiologists for the SELUTION Global Coronary Registry.
The SELUTION SLR drug-eluting balloon, available in over 40 countries, represents the next generation of drug-eluting balloon technology.
It offers sustained Sirolimus release without a permanent implant, allowing physicians to preserve future treatment options.
Cordis has been a leader in interventional cardiovascular and endovascular technology development and manufacturing for over 60 years.
The company remains dedicated to improving patient outcomes through innovation, clinical advancements, education, and service, with a mission to transform cardiovascular care.
Columbia University Irving Medical Center professor of medicine and Columbia Interventional Cardiovascular Care Program director Ajay Kirtane said: “Drug-eluting balloons are one of the most interesting and exciting new technologies in the coronary interventional space.
“The creation and initiation of this large real-world registry examining DEB utilization and the practice of PCI with this technology is a welcome development, which will help clinicians better understand where SELUTION SLR DEB can deliver the greatest benefits and improved outcomes in their practice.”
